Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis

Oncogene

Volumn 26, Issue 39, 2007, Pages 5828-5832

  Brien, G ^a,b,c,d   Trescol Biemont, M C ^a,b,c,d   Bonnefoy Berard N ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d IFR 128   (France)

Author keywords

Apoptosis; B lymphoma; Bcl 2; Bfl 1

Indexed keywords

BCL2 RELATED PROTEIN A1; CISPLATIN; DOXORUBICIN; FLUDARABINE; PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CISPLATIN; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, B-CELL; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; VIDARABINE; VINCRISTINE;

EID: 34548161868     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210363     Document Type: Article

References (25)

1. Cheng Q, Lee HH, Li Y, Parks TP, Cheng G. (2000). Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Oncogene 19: 4936-4940.
2. Coiffier B. (2005). State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 23: 6387-6393.
3. Cottalorda A, Verschelde C, Marcais A, Tomkowiak M, Musette P, Uematsu S et al. (2006). TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T-cell activation. Eur J Immunol 36: 1684-1693.
4. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ et al. (2006). Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354: 2431-2442.
5. Davis RE, Brown KD, Siebenlist U, Staudt LM. (2001). Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194: 1861-1874.
6. Feuerhake F, Kutok JL, Monti S, Chen W, Lacasce AS, Cattoretti G et al. (2005). NF{kappa}B activity, function and target gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 106: 1392-1399.
7. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C et al. (2005). Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23: 4117-4126.
8. Grumont RJ, Rourke IJ, Gerondakis S. (1999). Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 13: 400-411.
9. Hatada EN, Do RK, Orlofsky A, Liou HC, Prystowsky M, MacLennan IC et al. (2003). NF-kappaB1 p50 Is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappaB2 p100 to p52 in quiescent mature B cells. J Immunol 171: 761-768.
10. Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. (2002). Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 168: 5993-5996.
11. Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A et al. (2006). BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 24: 961-968.
12. Kuss AW, Knodel M, Berberich-Siebelt F, Lindemann D, Schimpl A, Berberich I. (1999). A1 expression is stimulated by CD40 in B cells and rescues WEHI 231 cells from anti-IgM-induced cell death. Eur J Immunol 29: 3077-3088.
13. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M et al. (2005). Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 11: 28-40.
14. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. (1999). NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 96: 9136-9141.
15. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M et al. (2005). Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105: 1851-1861.
16. Morales AA, Olsson A, Celsing F, Osterborg A, Jondal M, Osorio LM. (2005). High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int J Cancer 113: 730-737.
17. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C et al. (2003). Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101: 4279-4284.
18. Reed JC, Pellecchia M. (2005). Apoptosis-based therapies for hematologic malignancies. Blood 106: 408-418.
19. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R et al. (2005). Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23: 5027-5033.
20. Trescol-Biemont MC, Verschelde C, Cottalorda A, Bonnefoy-Berard N. (2004). Regulation of A1/Bfl-1 expression in peripheral splenic B cells. Biochimie 86: 287-294.
21. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. (1985). Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1443.
22. Wang CY, Guttridge DC, Mayo MW, Baldwin Jr AS. (1999). NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19: 5923-5929.
23. Werner AB, de Vries E, Tait SW, Bontjer I, Borst J. (2002). Bcl-2 family member Bfl-1/A1 sequesters truncated bid to inhibit is collaboration with pro-apoptotic Bak or Bax. J Biol Chem 277: 22781-22788.
24. Willis SN, Adams JM. (2005). Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 17: 617-625.
25. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. (1999). The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 13: 382-387.